Rodney Markin Biography and Net Worth

Director of Cardiff Oncology


Rodney Markin, MD, PhD, has been Chairman of the Board since December 2020 and served as a Director from February 2014 to December 2020. He is currently Vice President for Network Development, Nebraska Medicine and Associate Vice Chancellor for Business and Executive Director of the UNeTech Institute at the University of Nebraska Medical Center, a public center of health sciences research, patient care, and education, where he has served since July 1985. Dr. Markin also serves concurrently as Courtesy Professor of Psychiatry and Courtesy Professor of Surgery at the University of Nebraska and David T. Purtilo Distinguished Professor of Pathology and Microbiology since 2005 and Professor of Pathology and Microbiology. He serves on the boards of Perceptimed Inc. since 2014, MikroScan Technologies Inc. since 2015, Afaxys Inc. since 2017, and Paradigm Diagnostics Inc. since 2018. In the non-profit sector, Dr. Markin serves as a Director of Children’s Hospital and Medical Center Foundation and as Trustee for Keck Graduate Institute, and the Make-A-Wish Foundation, since 2015. Previously, Dr. Markin served as Chief Technology Officer and Associate Vice Chancellor for Business Development at the University of Nebraska from 2011 to 2017, and as Director of Transgenomic, Inc. from 2007 to 2014. The Board believes Dr. Markin’s medical insight, board experience and executive experience in institutional healthcare qualifies him to serve as a director of our company.

What is Rodney S. Markin's net worth?

The estimated net worth of Rodney S. Markin is at least $30,591.06 as of March 26th, 2021. Dr. Markin owns 7,181 shares of Cardiff Oncology stock worth more than $30,591 as of December 22nd. This net worth estimate does not reflect any other investments that Dr. Markin may own. Learn More about Rodney S. Markin's net worth.

How do I contact Rodney S. Markin?

The corporate mailing address for Dr. Markin and other Cardiff Oncology executives is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. Cardiff Oncology can also be reached via phone at (858) 952-7570 and via email at [email protected]. Learn More on Rodney S. Markin's contact information.

Has Rodney S. Markin been buying or selling shares of Cardiff Oncology?

Rodney S. Markin has not been actively trading shares of Cardiff Oncology during the past quarter. Most recently, on Friday, March 26th, Rodney S. Markin bought 2,900 shares of Cardiff Oncology stock. The stock was acquired at an average cost of $10.32 per share, with a total value of $29,928.00. Following the completion of the transaction, the director now directly owns 7,181 shares of the company's stock, valued at $74,107.92. Learn More on Rodney S. Markin's trading history.

Who are Cardiff Oncology's active insiders?

Cardiff Oncology's insider roster includes John Brancaccio (Director), Mark Erlander (CEO), Vicki Kelemen (COO), James Levine (CFO), Rodney Markin (Director), and Gary Pace (Director). Learn More on Cardiff Oncology's active insiders.

Are insiders buying or selling shares of Cardiff Oncology?

In the last year, Cardiff Oncology insiders bought shares 1 times. They purchased a total of 350,115 shares worth more than $910,299.00. The most recent insider tranaction occured on December, 11th when Director Gary W Pace bought 350,115 shares worth more than $910,299.00. Insiders at Cardiff Oncology own 7.8% of the company. Learn More about insider trades at Cardiff Oncology.

Information on this page was last updated on 12/11/2024.

Rodney S. Markin Insider Trading History at Cardiff Oncology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/26/2021Buy2,900$10.32$29,928.007,181View SEC Filing Icon  
See Full Table

Rodney S. Markin Buying and Selling Activity at Cardiff Oncology

This chart shows Rodney S Markin's buying and selling at Cardiff Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cardiff Oncology Company Overview

Cardiff Oncology logo
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $4.26
Low: $4.20
High: $4.67

50 Day Range

MA: $3.08
Low: $2.31
High: $5.35

2 Week Range

Now: $4.26
Low: $1.41
High: $6.42

Volume

2,098,097 shs

Average Volume

1,215,761 shs

Market Capitalization

$217.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89